Search clinical trials for: OBE2109

Total 9 results

ObsEva SA

Completed

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PRIMROSE 1)

Uterine Fibroids | Heavy Menstrual Bleeding

United States
ObsEva SA

Completed

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PRIMROSE 2)

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Bulgaria, Czechia, Hungary, Latvia, Lithuania, Poland, Romania, Ukraine
Bio Genuine (Shanghai) Biotech Co., Ltd.

Recruiting

Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis

Endometriosis | Moderate to Severe Endometriosis-associated Pain

China
ObsEva SA

Completed

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis (EDELWEISS)

Endometriosis

United States, Poland, Russian Federation, Ukraine
Bio Genuine (Shanghai) Biotech Co., Ltd.

Recruiting

Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.

Uterine Fibroids | Heavy Menstrual Bleeding

China
ARCAGY/ GINECO GROUP
Merck Sharp & Dohme LLC; OSE Immunotherapeutics

Recruiting

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (TEDOVA)

Relapsed Ovarian Cancer | Platinum-sensitive Ovarian Cancer

Belgium, France, Germany
Bio Genuine (Shanghai) Biotech Co., Ltd.

Not yet recruiting

Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures

Assisted Reproductive Technology | Controlled Ovarian Hyperstimulation

China
OSE Immunotherapeutics

Terminated

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure (ATALANTE-1)

Non Small Cell Lung Cancer

France, Spain, Israel, United States, United Kingdom, Italy, Poland, Czechia, Germany, Hungary
GERCOR - Multidisciplinary Oncology Cooperative...
OSE Immunotherapeutics

Recruiting

Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM)

Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Locally Advanced Cancer

France

Search clinical trials for: OBE2109

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations